Nakamura Ikuko, Oyama Jun-ichi, Komoda Hiroshi, Shiraki Aya, Sakamoto Yoshiko, Taguchi Isao, Hiwatashi Atsushi, Komatsu Aiko, Takeuchi Masayoshi, Yamagishi Sho-ichi, Inoue Teruo, Node Koichi
Department of Cardiovascular Medicine, Saga University, Saga 849-8501, Japan.
Cardiovasc Diabetol. 2014 Jan 14;13:15. doi: 10.1186/1475-2840-13-15.
The purpose of this study was to elucidate the effects of glimepiride on the levels of biomarkers related to cardiovascular regulation in patients with type 2 diabetes mellitus.
Thirty-four patients with type 2 diabetes received glimepiride for 24 weeks. Significant decreases in the levels of glyceraldehyde-derived advanced glycation end products, (glycer-AGE: toxic AGE), eotaxin and fibroblast growth factor (FGF)-2 were recognized after the administration of glimepiride. Moreover, there were trends for there to be increases in the levels of granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage-colony stimulating factor (GM-CSF), and decreases in the levels of fractalkine, soluble CD40 ligand (sCD40L), macrophage inflammatory protein (MIP)-β, vascular endothelial growth factor (VEGF) and soluble receptor for AGE (sRAGE).
Glimepiride may have potent anti-oxidative, anti-inflammatory and angiogenic properties and it may potentially repair tissue damage by decreasing the levels of toxic AGE and increasing colony-stimulating factors.
本研究旨在阐明格列美脲对2型糖尿病患者心血管调节相关生物标志物水平的影响。
34例2型糖尿病患者接受格列美脲治疗24周。服用格列美脲后，甘油醛衍生的晚期糖基化终产物（甘油-AGE：毒性AGE）、嗜酸性粒细胞趋化因子和成纤维细胞生长因子（FGF）-2水平显著降低。此外，粒细胞集落刺激因子（G-CSF）和粒细胞巨噬细胞集落刺激因子（GM-CSF）水平有升高趋势，而趋化因子、可溶性CD40配体（sCD40L）、巨噬细胞炎性蛋白（MIP）-β、血管内皮生长因子（VEGF）和可溶性AGE受体（sRAGE）水平有降低趋势。
格列美脲可能具有强大的抗氧化、抗炎和血管生成特性，并且可能通过降低毒性AGE水平和增加集落刺激因子来潜在地修复组织损伤。
Zotero 插件
